Solasia Pharma K.K.
Solasia Pharma K.K. scores highest on Nitro (46) and lowest on Price (6). Its PosiPenta is 30.07 out of 100, weaker than most similar companies.
On the Penta Grid this week, Solasia Pharma K.K. is Grid #51 of 53 in the Healthcare sector in Japan, and Grid #1,009 of 1,059 in Japan.
Compared with similar companies in the Healthcare sector in Japan.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Solasia Pharma K.K. | 30.07 | 6 | 42 | 46 | 37 | 19 |
| Koken Ltd. | 60.00 | 90 | 80 | 33 | 39 | 58 |
| Cosmo Bio Company,Limited | 58.42 | 62 | 55 | 60 | 57 | 58 |
| Yamashita Health Care Holdings,Inc. | 65.52 | 64 | 87 | 70 | 50 | 57 |
| Create Medic Co., Ltd. | 61.79 | 67 | 53 | 79 | 51 | 59 |
| Morishita Jintan Co., Ltd. | 70.43 | 84 | 84 | 68 | 50 | 66 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -8.51 |
| P/B ratio | 5.26 |
EEarnings
| Trailing EPS | ₹-1.99 |
| Forward EPS | ₹-1.27 |
NNitro
| Price | 16.95 |
| 52-week high | 25.43 |
| 52-week low | 12.71 |
| Fall from 52-week high | 33.3% |
TTorque
| Return on equity (ROE) | -65.98% |
| Debt-to-equity | 0.05 |
AAnchor
| Beta (price swings) | 1.18 |
| Market cap | ₹462 Cr |
| Insider holding | 14.62% |
| Dividend yield | 0.00% |
Figures as used for the week of 24 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Solasia Pharma K.K.'s PosiPenta score?
Solasia Pharma K.K.'s PosiPenta is 30.07 out of 100 for the week of 24 Oct 2026, based on 5 of 5 pillars.
Where does Solasia Pharma K.K. stand on the Penta Grid?
On the Penta Grid this week, Solasia Pharma K.K. is Grid #51 of 53 in the Healthcare sector in Japan, and Grid #1,009 of 1,059 in Japan.
Which PosiPenta pillar is strongest for Solasia Pharma K.K.?
Nitro (momentum), with a score of 46 out of 100: around the middle of similar companies.
Which PosiPenta pillar is weakest for Solasia Pharma K.K.?
Price (valuation), with a score of 6 out of 100: much weaker than most similar companies.
PositoAI is for research and education only and is not investment advice.